Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease
Neurology Live,
Samantha B. Haeberlein, PhD Biogen and Denali have announced that they are discontinuing a portion of the clinical development…
LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson’s disease patients
Overview of attention for article published in Journal of Neural Transmission, June 2010
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (80th percentile)
-
Good Attention Score compared to outputs of the same age and source (66th percentile)
Readers on
- mendeley
- 48 Mendeley
- citeulike
- 1 CiteULike